共 22 条
- [1] Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trialANNALS OF INTENSIVE CARE, 2023, 13 (01)Martin-Loeches, IgnacioShorr, Andrew F.Wunderink, Richard G.Kollef, Marin H.Timsit, Jean-FrancoisYu, BrianHuntington, Jennifer A.Jensen, ErinBruno, Christopher J.
- [2] Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trialCritical Care, 25Jean-François TimsitJennifer A. HuntingtonRichard G. WunderinkNobuaki ShimeMarin H. KollefÜlo KivistikMartin NováčekÁlvaro Réa-NetoIgnacio Martin-LoechesBrian YuErin H. JensenJoan R. ButtertonDominik J. WolfElizabeth G. RheeChristopher J. Bruno
- [3] Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trialCRITICAL CARE, 2021, 25 (01)Timsit, Jean-FrancoisHuntington, Jennifer A.Wunderink, Richard G.Shime, NobuakiKollef, Marin H.Kivistik, UloNovacek, MartinRea-Neto, AlvaroMartin-Loeches, IgnacioYu, BrianJensen, Erin H.Butterton, Joan R.Wolf, Dominik J.Rhee, Elizabeth G.Bruno, Christopher J.
- [4] Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP TrialINFECTIOUS DISEASES AND THERAPY, 2020, 9 (04) : 953 - 966Lodise, ThomasYang, JoePuzniak, Laura A.Dillon, RyanKollef, Marin
- [5] Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP TrialInfectious Diseases and Therapy, 2020, 9 : 953 - 966Thomas LodiseJoe YangLaura A. PuzniakRyan DillonMarin Kollef
- [6] Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP)ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)Huntington, Jennifer A.Yu, BrianLi, LinpingJensen, ErinBruno, ChristopherBoakye, MathewZhang, ZufeiGao, WeiFeng, Hwa-PingRhee, Elizabeth
- [7] Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trialLANCET INFECTIOUS DISEASES, 2019, 19 (12): : 1299 - 1311Kollef, Marin H.Novacek, MartinKivistik, UloRea-Neto, AlvaroShime, NobuakiMartin-Loeches, IgnacioTimsit, Jean-FrancoisWunderink, Richard G.Bruno, Christopher J.Huntington, Jennifer A.Lin, GinaYu, BrianButterton, Joan R.Rhee, Elizabeth G.
- [8] Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenemCritical Care, 26Marin H. KollefJean-François TimsitIgnacio Martin-LoechesRichard G. WunderinkJennifer A. HuntingtonErin H. JensenBrian YuChristopher J. Bruno
- [9] Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenemCRITICAL CARE, 2022, 26 (01)Kollef, Marin H.Timsit, Jean-FrancoisMartin-Loeches, IgnacioWunderink, Richard G.Huntington, Jennifer A.Jensen, Erin H.Yu, BrianBruno, Christopher J.
- [10] Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trialCritical Care, 25Andrew F. ShorrChristopher J. BrunoZufei ZhangErin JensenWei GaoHwa-Ping FengJennifer A. HuntingtonBrian YuElizabeth G. RheeCarisa De AndaSumit BasuMarin H. Kollef